<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467363</url>
  </required_header>
  <id_info>
    <org_study_id>EAGeR</org_study_id>
    <nct_id>NCT00467363</nct_id>
  </id_info>
  <brief_title>The Effects of Aspirin in Gestation and Reproduction</brief_title>
  <acronym>EAGeR</acronym>
  <official_title>The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to help elucidate the effects of low-dose aspirin in
      combination with folic acid on the incidence of live births and spontaneous abortions among a
      group of women who become pregnant compared to a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the fundamental nature of reproduction, for many it is a process fraught with
      frustration, inefficiency and imperfections, the effects of which can be severe. Infertility
      affects 10-15% of couples attempting to conceive. Among all women who conceive, the incidence
      of spontaneous abortion (SA) has been estimated to be between 15 and 31%, and in many cases
      the cause is unknown. Additionally, of the four million births yearly in the United States,
      between 8 and 15% will be born prematurely and experience increased morbidity and mortality
      as a result. An intervention with even a small absolute effect on any of these outcomes has
      great implications at the population level due to the large potential attributable benefit.

      One such potential intervention is low-dose acetylsalicylic-acid (aspirin). Aspirin has been
      a primary target of interest because of its anti-inflammatory, vasodilatory and platelet
      aggregation inhibition properties. To evaluate the effects of low-dose aspirin in combination
      with folic acid on the incidence of live births and spontaneous abortion, we are conducting a
      multi-site randomized controlled trial study with two sites and one data coordinating center.
      Women aged 18-40 currently trying to become pregnant and who have had a single spontaneous
      abortion in the past year will be eligible for the study. The recruitment goal is 1600 women.
      Participating women will be randomly assigned to one of two treatment groups. Those
      randomized to treatment will receive daily low-dose aspirin. Those randomized to placebo will
      receive daily placebo. Both groups will receive folic acid daily in accordance with
      recommendations from the U.S. Public Health Service for prevention of birth defects. The
      duration of treatment regimens (LDA and folic acid or placebo and folic acid) will be 6
      menstrual cycles, with those who become pregnant continuing until the end of pregnancy.
      Monthly urine and blood samples will be collected and questionnaires administered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth</measure>
    <time_frame>after delivery</time_frame>
    <description>Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hCG Recognized Pregnancy</measure>
    <time_frame>within 8-weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Recognized Pregnancy</measure>
    <time_frame>8-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Pregnancy Loss (EPL)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Implantation failures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Losses Occurring Less Than 10 Weeks</measure>
    <time_frame>less than 10-weeks</time_frame>
    <description>Includes preembryonic and embryonic losses (exclusive of implantation failures)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal Pregnancy Loss</measure>
    <time_frame>until 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stillbirth</measure>
    <time_frame>40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic Pregnancy</measure>
    <time_frame>within 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molar Pregnancy</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for Gestational Age Infant</measure>
    <time_frame>until delivery</time_frame>
    <description>birthweight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth</measure>
    <time_frame>until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Fetal Testing</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal Intolerance of Labor</measure>
    <time_frame>until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abruption</measure>
    <time_frame>until delivery</time_frame>
    <description>Partial or complete abruption (ie, premature separation of the placenta)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1228</enrollment>
  <condition>Birth</condition>
  <condition>Spontaneous Abortion</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>400micrograms of folic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic-acid (aspirin)</intervention_name>
    <description>81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid</intervention_name>
    <description>400micrograms of folic acid.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women experiencing one or two pregnancy losses at any point in gestation in the past
             that were not elective termination(s). At least one of these losses must be well
             documented by one of the following:

               -  Sonogram demonstrating anembryonic loss, embryonic loss or fetal death.

               -  Histologic confirmation of products of conception that were spontaneously passed
                  per vagina or surgically obtained.

               -  Hospital records of fetus delivery.

               -  Late menses and positive serum hCG or positive urine hCG documented by hospital
                  or clinic records followed by either a negative hospital/clinic pregnancy test or
                  a decline in urinary hCG level over 3 days.

               -  Home pregnancy tests without hCG confirmation from a healthcare provider (either
                  serum or urine) will not be accepted.

          -  No more than 5 pregnancies in total including the pregnancy loss(es).*

          -  Up to two prior pregnancies that did not end in a loss.*

             *Women may have up to two pregnancies beyond 20 weeks that were not losses, two
             spontaneous pregnancy losses at any time in the past, and up to one therapeutic or
             elective termination (two therapeutic or elective terminations if no other
             pregnancies). Ectopic and molar pregnancies would, for the purpose of enrollment, be
             considered in the same category as therapeutic termination pregnancies. Women with
             more than two live births or those with more than two losses, regardless of the week
             of gestation of the loss, are excluded.

          -  Presence of intact tubes (both), ovaries (both), and uterus.

          -  Between 18 and 40 years of age at time of baseline visit.

          -  Regular menstrual periods between 21 - 42 days in length (within the last 12 months).
             Regular menstrual periods are defined as no more than an 8-day difference between the
             woman's shortest and longest cycle.

          -  No more than one missed menses in the past 12 months (other than those missed due to
             pregnancy or breastfeeding).

          -  Actively trying to conceive with a male partner and not using contraception by the
             baseline visit.

          -  Not currently pregnant at the baseline or randomization visits.

          -  Ability and willingness to give informed consent.

          -  Willingness to be randomized and to take daily study pills for 6 months to a possible
             15 months

        Exclusions Criteria:

          -  Known allergies to aspirin or non-steroidal anti-inflammatory agents.

          -  Clinical indication for anticoagulant therapy. These include prior or current
             thrombosis, antiphospholipid syndrome (APS) or known major thrombophilia.

          -  Clinical indication for chronic use of NSAIDs such as rheumatoid arthritis.

          -  Indication for additional folic acid supplementation, such as prior infant with neural
             tube defect (NTD), seizure disorder.

          -  Medical contraindication to aspirin therapy. These include uncontrolled asthma, nasal
             polyps, bleeding disorders, or history of gastrointestinal ulcer.

          -  Presence of major medical disorders (regardless of severity). These include diabetes,
             hypertension, systemic lupus erythematosus (SLE), untreated or active cancer (any
             cancer in remission or non-melanoma skin cancer is not included in the exclusion
             criteria), liver disease, renal disease, rheumatoid arthritis, cardiac disease,
             pulmonary disease other than mild asthma, neurologic disease requiring medical
             treatment, uncontrolled hypothyroidism, uncontrolled seizure disorder. Untreated
             vitamin B12 deficiency, severe anemia (Hct &lt; 30%), hemophilia, gout, nasal polyps,
             among others.

          -  Currently undergoing/planned use of assisted reproductive techniques during trial
             (IVF; IUI; Clomid).

          -  History of infertility or sub-fertility. This includes any of the following:

               -  No conception after ≥ 1 year of unprotected intercourse and actively trying to
                  conceive.

               -  Any prior medical treatment for infertility.

               -  Prior treatment for known pelvic inflammatory disease.

               -  Known male infertility or sperm abnormality (current partner).

               -  Known tubal occlusion, anovulation, uterine abnormality, or endometriosis stage
                  III or IV.

               -  History of polycystic ovarian syndrome.

          -  Presence of unstable mental disorder. These include bipolar illness, schizophrenia,
             uncontrolled depression, uncontrolled anxiety disorder.

          -  Known current or recent alcohol abuse or illicit drug use.

          -  Current diagnosis of sexually transmitted infection (STI) (temporary exclusion)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique F Schisterman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Wactawski-Wende, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Silver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noya Galai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Haifa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janet Townsend, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Commonwealth Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Lynch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado, Denver School of Medicine, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Center, Department of Social and Preventive Medicine, University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses Taylor Hospital</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.nichd.nih.gov/about/org/diphr/eb/research/pages/effects-aspirin.aspx</url>
    <description>EAGeR Trial Home Page</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2007</study_first_submitted>
  <study_first_submitted_qc>April 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2007</study_first_posted>
  <results_first_submitted>April 10, 2014</results_first_submitted>
  <results_first_submitted_qc>April 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2014</results_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</investigator_affiliation>
    <investigator_full_name>Enrique Schisterman</investigator_full_name>
    <investigator_title>Chief and Senior Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited using community-based advertisements and physician referral to four university medical centres in the US (2006–12).</recruitment_details>
      <pre_assignment_details>Out of the 1397 women with confirmed eligibility, consented, and expressed initial interest in the study, 60 (4.3%) chose to discontinue the enrolment process. An additional 109 (7.8%) tested positive for pregnancy at the baseline visit or became pregnant before their randomisation visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aspirin</title>
          <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="615"/>
                <participants group_id="P2" count="613"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="535"/>
                <participants group_id="P2" count="543"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All women who consented and underwent randomization were included in baseline analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Aspirin</title>
          <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="615"/>
            <count group_id="B2" value="613"/>
            <count group_id="B3" value="1228"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="4.9"/>
                    <measurement group_id="B2" value="28.7" spread="4.7"/>
                    <measurement group_id="B3" value="28.7" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="615"/>
                    <measurement group_id="B2" value="613"/>
                    <measurement group_id="B3" value="1228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="576"/>
                    <measurement group_id="B2" value="586"/>
                    <measurement group_id="B3" value="1162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Live Birth</title>
        <description>Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff .</description>
        <time_frame>after delivery</time_frame>
        <population>Analyses were based on the intention-to-treat principle (excluding participants lost to follow-up).</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth</title>
          <description>Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff .</description>
          <population>Analyses were based on the intention-to-treat principle (excluding participants lost to follow-up).</population>
          <units>livebirths</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was designed to detect a 10% absolute difference in livebirth rate with 80% power and a type I error rate of 5%, on the assumption that participants taking placebo who achieved pregnancy would have a livebirth rate of 75%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0984</p_value>
            <p_value_desc>Only one outcome for primary outcome, so no adjustment of p-value for multiple comparisons was done. A priori threshold for statistical significance was p&lt;0.05.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>No adjustments were done. Treatment groups were similar with respect to the assessed demographic and baseline characteristics</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hCG Recognized Pregnancy</title>
        <time_frame>within 8-weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>hCG Recognized Pregnancy</title>
          <units>pregnancy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="394"/>
                    <measurement group_id="O2" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0165</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Recognized Pregnancy</title>
        <time_frame>8-weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Recognized Pregnancy</title>
          <units>pregnancy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374"/>
                    <measurement group_id="O2" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0329</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Pregnancy Loss (EPL)</title>
        <description>Implantation failures</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Pregnancy Loss (EPL)</title>
          <description>Implantation failures</description>
          <units>pregnancy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="537"/>
                <count group_id="O2" value="551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.8902</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.64</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Losses Occurring Less Than 10 Weeks</title>
        <description>Includes preembryonic and embryonic losses (exclusive of implantation failures)</description>
        <time_frame>less than 10-weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Losses Occurring Less Than 10 Weeks</title>
          <description>Includes preembryonic and embryonic losses (exclusive of implantation failures)</description>
          <units>pregnancy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="537"/>
                <count group_id="O2" value="551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.6869</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.76</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal Pregnancy Loss</title>
        <time_frame>until 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Pregnancy Loss</title>
          <units>pregnancy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="537"/>
                <count group_id="O2" value="551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.7530</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.19</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stillbirth</title>
        <time_frame>40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Stillbirth</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="537"/>
                <count group_id="O2" value="551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.15</ci_lower_limit>
            <ci_upper_limit>7.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ectopic Pregnancy</title>
        <time_frame>within 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Ectopic Pregnancy</title>
          <units>pregnancy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="537"/>
                <count group_id="O2" value="551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.21</ci_lower_limit>
            <ci_upper_limit>5.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Molar Pregnancy</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Molar Pregnancy</title>
          <units>pregnancy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.21</ci_lower_limit>
            <ci_upper_limit>5.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preeclampsia</title>
        <time_frame>until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Preeclampsia</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.7943</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.67</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Small for Gestational Age Infant</title>
        <description>birthweight</description>
        <time_frame>until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Small for Gestational Age Infant</title>
          <description>birthweight</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3327" spread="521"/>
                    <measurement group_id="O2" value="3315" spread="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.7802</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preterm Birth</title>
        <time_frame>until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Birth</title>
          <units>infants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.2603</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.42</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Fetal Testing</title>
        <time_frame>8 weeks</time_frame>
        <population>No data were collected for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Fetal Testing</title>
          <population>No data were collected for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal Intolerance of Labor</title>
        <time_frame>until delivery</time_frame>
        <population>No data were collected for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Intolerance of Labor</title>
          <population>No data were collected for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abruption</title>
        <description>Partial or complete abruption (ie, premature separation of the placenta)</description>
        <time_frame>until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Abruption</title>
          <description>Partial or complete abruption (ie, premature separation of the placenta)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="615"/>
                <count group_id="O2" value="613"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aspirin</title>
          <description>81mg of low-dose aspirin plus 400micrograms of folic acid.
acetylsalicylic-acid (aspirin): 81mg of low-dose aspirin plus 400micrograms of folic acid.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>400micrograms of folic acid.
Folic acid: 400micrograms of folic acid.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="615"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Transient Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="615"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="613"/>
              </event>
              <event>
                <sub_title>Minor Birth Defects</sub_title>
                <description>No difference was seen in the proportion of minor birth defects between the groups (four in each group). Of the four birth defects in the low dose aspirin group, one was a cleft lip and three were ventricular septal defects.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="615"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="613"/>
              </event>
              <event>
                <sub_title>Neonatal Death</sub_title>
                <description>Three cases of neonatal death occurred; of the two deaths in the lowdose aspirin group, one was due to cervical insufficiency and the other was attributed to chronic vaginal bleeding, chorioamnionitis, and preterm birth.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="615"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="615"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Vaginal Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="615"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="613"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Enrique Schisterman</name_or_title>
      <organization>NICHD</organization>
      <phone>(301) 435-6893</phone>
      <email>schistee@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

